CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 40 target
Drug / intervention
Atezolizumab +1 moredrug
Likely dose
Not stated in record
Key inclusion· 10
  • ✓Pathologically confirmed residual invasive breast cancer in breast and/or lymph nodes post-neoadjuvant chemotherapy
  • ✓HER2 negative by ISH or IHC 0/1+
  • ✓ER and PR negative (<10% of cells) by IHC
  • ✓Prior neoadjuvant chemotherapy before breast surgery
Key exclusion· 22
  • ✕Prior therapy with sacituzumab govitecan, irinotecan, or topoisomerase I-containing antibody-drug conjugates
  • ✕Receipt of adjuvant chemotherapy
  • ✕Clinical or radiographic evidence of metastatic disease
  • ✕Residual DCIS or LCIS alone or pT0N0i and pT0N1mic disease

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04434040
NCT04434040Phase 2RecruitingOn Track
Long Recruiting
CompareCT.gov

A Single Arm Phase 2 Trial of Atezolizumab With Sacituzumab Govitecan to Prevent Recurrence in Triple Negative Breast Cancer (ASPRIA)

Dana-Farber Cancer Institute·interventional·Posted Jun 16, 2020·Updated May 4, 2026

In Brief

A Phase 2 clinical trial evaluating Atezolizumab and Sacituzumab govitecan for Breast Cancer and 3 related conditions. Currently recruiting, targeting 40 participants across 7 sites.

Detailed Summary

The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacituzumab govitecan * Atezolizumab

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Triple Negative Breast Cancer, Residual Cancer, Circulating Tumor DNA
CountriesUnited States
CollaboratorsGenentech, Inc., Stand Up To Cancer

Timeline

Phase 2Recruiting
20212022202320242025202620272028
First PostedJun 16, 2020
Enrollment StartJul 2, 2020
Primary CompletionDec 30, 2026
Study CompletionDec 30, 2027
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 6.0 years agoPrimary completion in 6 months

Interventions

Atezolizumabdrug

Atezolizumab is a type of antibody and is administered intravenously.

Sacituzumab govitecandrug

Sacituzumab govitecan is an antibody drug conjugate and is administered intravenously